Floatz logo

Tinodasertib

Chronic Myeloid Leukemia Accelerated Phase (CML-AP, Ph+)

EDDC (Experimental Drug Development Centre), A*STAR Research EntitiesSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Chronic Myeloid Leukemia Accelerated Phase (CML-AP, Ph+) cohort.

Asset / SponsorPhaseRating
Fludarabine
University of Illinois at Chicago
Phase 2BBB
CYCLOSPORIN A
University of Michigan Rogel Cancer Center
Phase 2BBB
Cyclophosphamide
University of Illinois at Chicago
Phase 2BBB
METHOTREXATE
University of Michigan Rogel Cancer Center
Phase 2BB
TACROLIMUS
University of Michigan Rogel Cancer Center
Phase 2BB

View all 46 →

Same molecule, other indications

Tinodasertib is also rated in:

colorectal cancerDormant
CCC
Indicative ·
48 / 100
View asset →
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
CC
Indicative ·
43 / 100
View asset →
acute lymphoblastic leukemiaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →